Boston Scientific Co. (NYSE:BSX) Shares Acquired by Heritage Investors Management Corp

Heritage Investors Management Corp lifted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 9.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 112,677 shares of the medical equipment provider’s stock after purchasing an additional 9,616 shares during the period. Heritage Investors Management Corp’s holdings in Boston Scientific were worth $5,095,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. NuWave Investment Management LLC boosted its holdings in shares of Boston Scientific by 111.4% during the 3rd quarter. NuWave Investment Management LLC now owns 721 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 380 shares during the last quarter. Optimum Investment Advisors boosted its holdings in shares of Boston Scientific by 100.0% during the 3rd quarter. Optimum Investment Advisors now owns 800 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 400 shares during the last quarter. Compagnie Lombard Odier SCmA acquired a new position in shares of Boston Scientific during the 2nd quarter worth approximately $34,000. Executive Wealth Management LLC boosted its holdings in shares of Boston Scientific by 58.8% during the 3rd quarter. Executive Wealth Management LLC now owns 1,151 shares of the medical equipment provider’s stock worth $46,000 after purchasing an additional 426 shares during the last quarter. Finally, Evoke Wealth LLC acquired a new position in shares of Boston Scientific during the 3rd quarter worth approximately $47,000. Institutional investors and hedge funds own 91.05% of the company’s stock.

Several research firms have recently commented on BSX. Needham & Company LLC lowered shares of Boston Scientific from a “strong-buy” rating to a “buy” rating and set a $53.00 price target on the stock. in a research report on Thursday, December 19th. JPMorgan Chase & Co. lifted their price target on shares of Boston Scientific from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, December 20th. Raymond James reduced their price target on shares of Boston Scientific from $50.00 to $48.00 and set a “strong-buy” rating on the stock in a research report on Monday, October 14th. Stephens set a $48.00 price target on shares of Boston Scientific and gave the company a “buy” rating in a research report on Monday, September 30th. Finally, Cowen lifted their price target on shares of Boston Scientific from $47.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, December 30th. One analyst has rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $48.62.

Shares of NYSE BSX opened at $42.66 on Wednesday. The firm has a market cap of $63.66 billion, a price-to-earnings ratio of 29.02, a PEG ratio of 2.23 and a beta of 0.78. The company has a quick ratio of 0.77, a current ratio of 1.14 and a debt-to-equity ratio of 0.99. Boston Scientific Co. has a 52-week low of $34.35 and a 52-week high of $46.62. The business’s 50 day moving average is $44.60 and its two-hundred day moving average is $42.40.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.01. The company had revenue of $2.71 billion for the quarter, compared to analyst estimates of $2.68 billion. Boston Scientific had a return on equity of 23.10% and a net margin of 10.49%. The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.35 earnings per share. Analysts anticipate that Boston Scientific Co. will post 1.57 EPS for the current fiscal year.

In other Boston Scientific news, SVP Desiree Ralls-Morrison sold 4,050 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $45.50, for a total value of $184,275.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David A. Pierce sold 5,000 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $42.05, for a total transaction of $210,250.00. Following the completion of the transaction, the executive vice president now owns 29,201 shares of the company’s stock, valued at approximately $1,227,902.05. The disclosure for this sale can be found here. In the last three months, insiders sold 195,751 shares of company stock worth $8,680,501. 0.66% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: Penny Stocks

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply